about
Angiotensin receptor blockers in heart failure after the ELITE II trialNo effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 monthsMitral annular plane systolic excursion (MAPSE) in shock: a valuable echocardiographic parameter in intensive care patientsClinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial.Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).Differences in cardiovascular risk profile between electrocardiographic hypertrophy versus strain in asymptomatic patients with aortic stenosis (from SEAS data).High-sensitive cardiac Troponin T is superior to echocardiography in predicting 1-year mortality in patients with SIRS and shock in intensive careAortic stenosis and mitral regurgitation as predictors of atrial fibrillation during 11 years of follow-upPrimary hyperparathyroidism and heart disease--a review.The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.Myocardial structure and function by echocardiography in relation to glucometabolic status in elderly subjects from 2 population-based cohorts: a cross-sectional study.The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: a cross-sectional analysis within the Malmö Preventive Project.Assessing left ventricular systolic function in shock: evaluation of echocardiographic parameters in intensive care.Implications of CIBIS III: a commentary.Treatment of early heart failure: an ACEI or a beta-blocker first?The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.Sudden death prevention in heart failure: The case of CIBIS III.Association Between Erectile Function and Biomarkers of Subclinical Atherosclerosis: A Study Based on Middle-Aged Healthy Men from the General Population.Coronary flow velocity reserve reduction is comparable in patients with erectile dysfunction and in patients with impaired fasting glucose or well-regulated diabetes mellitus.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.Ferric carboxymaltose in patients with heart failure and iron deficiency.
P50
Q24792591-4459F572-09A4-49F6-BADD-E57C38884C22Q24804387-5ED5EC7A-8F03-4A06-ACE4-54E00B040196Q30453553-E913C775-AA63-41DE-AD0B-793AB09E411FQ33340564-FCDEAF36-5E4A-49A3-A079-AA15722C9DBBQ33889897-8D6432AD-5A3B-4E74-8AFA-25A158022CBDQ33915977-9FFD8F7F-E6C6-4DBD-98D1-AFF91C99B5E5Q34420169-C6968EB0-9848-427D-9693-F7AAC204B437Q34449557-E743E8D4-B115-4C2D-A01F-3DC0A77E91FDQ34649932-23009F14-31A8-408A-9DAA-7C6DC17EA5B0Q35549440-47AF191A-8B7B-4C49-ADAF-A59E52AC2689Q35623691-45518B7D-8079-4546-90AB-42CE087BC1B7Q35721370-77A06092-2C6D-471F-98B6-214E864F27DDQ36070532-403E0795-8A7F-427F-8E20-D4FE84DB8D51Q36416936-7421472D-D5C8-4D1D-A7A8-880A8C15AAB9Q36458367-4C526DB2-2C0B-4006-9FA8-12A8999C0D81Q36499172-96CE4F0D-7861-4987-AD24-57D2DCAFE00BQ37250239-FDD0339E-3F94-4A28-8B5F-2D3FB11E697EQ37405902-B687BA14-9733-4C07-8CB9-797C8D5DF6B9Q38255444-0EF6C4D5-B0DC-4529-ABD8-5E98685B2B54Q38389279-EF74BBC1-B161-4FA1-884A-1EE759990CB0Q38479930-ACDE0146-CB78-4F54-BD7C-447AF50D8B19Q38605422-203C39BF-A5A8-4971-8BDE-D2092057C513Q39170254-23E455D2-2CC7-498F-BD1A-A3748B658B49Q40221529-1F2386D1-1369-402D-B031-A50A5A3ED18CQ42666929-5BF6FB48-33DA-4A60-91DE-BC8B97C2DC19Q42795700-0EF3E636-CF4B-4015-AE94-A980C63D529BQ43032109-FED2D54A-6E8F-4604-A287-F596F71C2415Q43240282-793E2104-99ED-4DA4-99CC-C44069933AE2
P50
description
onderzoeker
@nl
name
Ronnie Willenheimer
@ast
Ronnie Willenheimer
@en
Ronnie Willenheimer
@es
Ronnie Willenheimer
@nl
Ronnie Willenheimer
@sl
type
label
Ronnie Willenheimer
@ast
Ronnie Willenheimer
@en
Ronnie Willenheimer
@es
Ronnie Willenheimer
@nl
Ronnie Willenheimer
@sl
prefLabel
Ronnie Willenheimer
@ast
Ronnie Willenheimer
@en
Ronnie Willenheimer
@es
Ronnie Willenheimer
@nl
Ronnie Willenheimer
@sl